EPICOR
Epicor, a global provider of industry-specific enterprise software to promote business growth, today announced its Partner Excellence Award winners at the Momentum Partner Conference 2022.
Now in its sixth year, the event recognises industry Partners that have outperformed in their commitment to the growth of Epicor business, through innovation and cloud technology with their customers.
“A record number of nominations were received this year and our Partners exceeded all expectations as they continued to demonstrate strong expertise and innovation in helping our customers,” said Paul Flannery, VP of International Channel Sales at Epicor.
At the virtual ceremony, Partners were recognized for their achievements across five categories showcasing excellence in industry expertise, business transformation, cloud transformation, and overall business success. Winners included:
Industry Specialist Award – Finsoft Consulting Sdn Bhd was named Industry Specialist winner for delivering a Best-in-Class solution for its customer – a leading supplier in the rubber glove industry, challenged in coping with rising market demand. The team customised a suite of Epicor solutions that solved challenges other ERP systems could not address. The integration enabled the customer to quadruple market share in a highly critical market.
Business Transformation Award – Grand Target Information Technology Ltd secured a win in the Business Transformation category after taking its customer on a comprehensive Industry 4.0 journey, engaging them in a change management experience throughout. The team improved its customer’s business workflow by opening data chains across ERP, PLM, MES and WMS systems, integrating module solutions, and migrating the customer toward a fully integrated digital twin smart factory.
Cloud Transformation Award – Panamax Infotech Ltd was awarded Cloud Transformation winner for delivering an impressive 80 percent of its business on new cloud accounts, winning deals during a time of challenging market conditions, and increasing deal sizes. Panamax also secured the first Epicor cloud customer in India, going live in less than six months.
Rising Star Award – This year’s rising star award went to Clear Business Outcome Ltd, chosen for significant growth through a regional focus and expertise in both sector and technology platform, its unique ‘Engine for Growth’ demand generation programmes, and its transformation from Consultancy to an end-to-end sales-led operational business model.
International Partner of the Year Award – Consistent performance over many years earned Aspera Solutions the coveted International Partner of the Year award, delivering strong and consistent year-over-year growth executed in each of Epicor’s strategic areas – cloud, key new accounts, migrations, add-on sales and platform sales on both Kinetic and Prophet 21 platforms.
“Congratulations to Aspera and all our winners! Partner recognition is very important to Epicor as we celebrate these achievements and international success. We thank you all for your hard work and commitment and look forward to accelerating our success over the next 12 months,” commented Andy Coussins, Senior Vice President and Head of International at Epicor.
For more information on the Epicor Partner Network please visit our website .
About Epicor
Epicor equips hard-working businesses with enterprise solutions that keep the world turning. For 50 years, Epicor customers in the automotive, building supply, distribution, manufacturing, and retail industries have trusted Epicor to help them do business better. Innovative Epicor solution sets are carefully curated to fit customer needs and built to respond flexibly to their fast-changing reality. With deep industry knowledge and experience, Epicor accelerates every customer’s ambition, whether to grow and transform, or simply become more productive and effective. Visit www.epicor.com for more information.
Epicor and the Epicor logo are trademarks of Epicor Software Corporation, registered in the United States and other countries. Other trademarks referenced are the property of their respective owners. The product and service offerings depicted in this document are produced by Epicor Software Corporation. Results are not guaranteed, and each user’s experience will vary.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220309005167/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
The Rock-It Company Expands Fine Art Logistics Capabilities of DIETL Through Acquisition of Several Strategic Infrastructure Services5.1.2026 15:00:00 CET | Press release
The acquisition strengthens DIETL’s fine art logistics operations through expanded access to specialized storage, handling and customs services. The Rock-It Company announced today that DIETL has acquired multiple fine art logistics specialists, strengthening its infrastructure and expanding access to specialized services across key U.S. art markets. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260105175923/en/ The Rock-It Company Expands Fine Art Logistics Capabilities of DIETL Through Acquisition of Several Strategic Infrastructure Services The acquired companies include Delaware Freeport, Delaware National Art Company, Techno Export, and Registrar Technologies. Together, these businesses add depth across fine art storage, handling, packing, crating, installation support, customs brokerage, and technology-enabled logistics services, complementing DIETL’s existing operations. Delaware Freeport, a provider of high-security
TII Launches Falcon Reasoning: Best 7B AI Model Globally, Also Outperforms Larger Models5.1.2026 14:54:00 CET | Press release
Falcon H1R 7B Packs Advanced Reasoning into a Compact 7 Billion Parameter Model Optimized for Speed and Efficiency TII’s Latest AI Model Outperforms Larger Rivals from Microsoft, Alibaba, and NVIDIA on Key Benchmarks The Technology Innovation Institute (TII), the applied research pillar of Abu Dhabi’s Advanced Technology Research Council (ATRC), has announced the release of Falcon H1R 7B, a next-generation AI model that takes a significant step toward making advanced AI more accessible than ever, by delivering world-class reasoning performance in a compact, efficient, and openly available format. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260105981339/en/ TII Launches Falcon Reasoning: Best 7B AI Model Globally, Also Outperforms Larger Models (Graphic: AETOSWire) With just 7 billion parameters, Falcon H1R 7B challenges and, in many cases, outperforms larger open-source AI models from around the world, including models fr
Curing the Incurable with ‘Biological Age Zero’ Cells: Clonell™ Launches the Ultimate Regenerative Medicine Platform5.1.2026 14:00:00 CET | Press release
Fundamental Cure for Intractable and Incurable Diseases using ‘Biological Age Zero’ Cells Derived from Patient’s Own Cells via SCNT TechnologyWorld's First Therapy Platform Simultaneously Solving Immune Rejection and Inheritance of Cellular Aging—The Major Hurdles of Existing Stem Cell TherapiesDrastically Improving Treatment Accessibility through the New Paradigm, ‘Patient-Initiated Clinical Trial™’, which Overcomes Existing Clinical Limitations Clonell Therapeutics, Inc., a leading biotechnology company dedicated to curing intractable and incurable diseases, announced today the official launch of the world's first 'Patient-Specific Embryonic Stem Cell (Somatic Cell Nuclear Transfer-derived Embryonic Stem Cell, hereinafter SCNT-ESC)' therapy platform based on Somatic Cell Nuclear Transfer (SCNT) technology. Concurrently, the company has initiated its innovative 'Patient-Initiated Clinical Trial™' to apply this breakthrough technology directly to patients. This platform launch is evalu
HELUS Pharma Propels Therapeutic Innovation in Mental Health and Commences Trading on Nasdaq5.1.2026 13:30:00 CET | Press release
Helus Pharma builds on the strong foundation originally created as Cybin Inc., reflecting the Company’s ongoing transformation to a commercial stage pharmaceutical company Helus Pharma commences trading on Nasdaq Global Market (“Nasdaq”) and on Cboe Canada under ticker symbol: HELP Helus Pharma continues to progress its portfolio of novel serotonergic agonists (“NSAs”), with the goal of developing treatments designed to redefine mental health care, including HLP004 for the treatment of generalized anxiety disorder, with Phase 2 topline data readout expected in Q1 2026 Preparations in progress for the commercialization of HLP003, Helus Pharma’s NSA in Phase 3 clinical development, which has been granted Breakthrough Therapy Designation by the FDA for the adjunctive treatment of major depressive disorder This news release constitutes a “designated news release” for the purpose of the Company’s prospectus supplement dated December 30, 2025, to it short form base shelf prospectus dated Sep
Incyte Announces Positive Topline Results from Pivotal Study of Tafasitamab (Monjuvi®/Minjuvi®) as a First-line Treatment for Diffuse Large B-Cell Lymphoma5.1.2026 13:30:00 CET | Press release
- Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®) and lenalidomide in addition to R-CHOP met its primary endpoint of progression-free survival (PFS) - Based on these results, Incyte plans to file a supplemental Biologics License Application (sBLA) for tafasitamab and lenalidomide in addition to R-CHOP in first-line diffuse large B-cell lymphoma (DLBCL) in the first half of 2026 Incyte (Nasdaq:INCY) today announced positive topline results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified cytolytic CD19 targeting monoclonal antibody, and lenalidomide in addition to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone) compared to R-CHOP alone as a first-line treatment for adults with newly diagnosed diffuse large B-cell lymphoma (DLBCL) with an International Prognostic Index (IPI) score of three to five (3-5) for patients >60 years o
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom